<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523924</url>
  </required_header>
  <id_info>
    <org_study_id>J1545</org_study_id>
    <secondary_id>IRB00062296</secondary_id>
    <nct_id>NCT02523924</nct_id>
  </id_info>
  <brief_title>Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy</brief_title>
  <official_title>Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel
      low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical
      prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18F-DCFPyL is a novel low-molecular weight PSMA imaging agent. A recent study of patients
      with metastatic prostate cancer found that PSMA PET/CT identified more sites of disease than
      conventional imaging with CT, MRI and bone scan. In this study we aim to investigate
      18F-DCFPyL PET/CT in patients with an elevated PSA following radical prostatectomy. During
      the course of this study, patients will undergo two 18F-DCPyL PET/CT scans. The first scan
      will take place within 45 days of staging imaging and the second will take place following
      six months of standard of care therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2015</start_date>
  <completion_date type="Actual">March 4, 2019</completion_date>
  <primary_completion_date type="Actual">November 4, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT</measure>
    <time_frame>6 months</time_frame>
    <description>Number of sites with 18F-DCFPyL uptake consistent with prostate cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Location of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT</measure>
    <time_frame>6 months</time_frame>
    <description>Location of uptake of 18F-DCFPyL consistent with prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of 18F-DCFPyL PET/CT Findings With Prostate Specific Antigen (PSA) Levels</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with PSA 0.2-1.0ng/mL OR PSA &gt;1.0ng/mL with at least 1 site of uptake of 18F-DCFPyL consistent with prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Findings on 18FDCFPyL PET/CT With Those Found on Conventional Imaging (Bone Scan and Cross-sectional Imaging)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of sites with uptake on 18F-DCFPyL PET/CT and corresponding lesions identified on conventional imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Findings on 18F-DCFPyL PET/CT With Tissue Histology and PSMA Expression of Biopsied/Resected Pathology Specimens</measure>
    <time_frame>6 months</time_frame>
    <description>Number of sites with 18F-DCFPyL uptake from which biopsy specimens show PSMA expression.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of 18F-DCFPyL PET/CT Findings With Time to Disease Progression</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Treatment Response by 18F-DCFPyL PET/CT</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <arm_group>
    <arm_group_label>18F-DCFPyL PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-DCFPyL</intervention_name>
    <description>18F-DCFPyL PET/CT</description>
    <arm_group_label>18F-DCFPyL PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  History of adenocarcinoma of the prostate treated with radical prostatectomy

          -  Serum PSA level ≥0.2 ng/mL at least 45 days prior to study enrollment

          -  Completed staging evaluation with bone scan as well as CT or MRI of the abdomen and
             pelvis at least 45 days prior to study enrollment

        Exclusion Criteria:

          -  Intention to enroll in a blinded therapeutic clinical trial

          -  History of other malignancy diagnosed within the last three years (the exception of
             squamous cell or basal cell carcinoma of the skin)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SKCCC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <results_first_submitted>January 22, 2020</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2020</results_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02523924/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>19 patients did not meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>18F-DCFPyL PET/CT</title>
          <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>18F-DCFPyL PET/CT</title>
          <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="45" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months since radical prostatectomy</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="4" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason grade group</title>
          <description>The Gleason score ranges from 2-10 with a higher score reflecting less-differentiated tumors with worse prognosis. The total score is a sum of two numbers which are based on the microscopic appearance of cells. The first number is the score based on the dominant, cell morphology (scored 1-5) and the second number is based on the highest grade of the non-dominant cell pattern (scored 1-5)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pathologic stage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>pT2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>pT3a</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>pT3b</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive surgical margin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.4" lower_limit="0.2" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT</title>
        <description>Number of sites with 18F-DCFPyL uptake consistent with prostate cancer.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>18F-DCFPyL PET/CT</title>
            <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT</title>
          <description>Number of sites with 18F-DCFPyL uptake consistent with prostate cancer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>at least 1 site</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 1 site</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no sites</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Location of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT</title>
        <description>Location of uptake of 18F-DCFPyL consistent with prostate cancer.</description>
        <time_frame>6 months</time_frame>
        <population>Location of 18F-DCFPyL uptake could only be assessed in patients with at least 1 site of 18F-DCFPyL uptake (26/31)</population>
        <group_list>
          <group group_id="O1">
            <title>18F-DCFPyL PET/CT</title>
            <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
          </group>
        </group_list>
        <measure>
          <title>Location of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT</title>
          <description>Location of uptake of 18F-DCFPyL consistent with prostate cancer.</description>
          <population>Location of 18F-DCFPyL uptake could only be assessed in patients with at least 1 site of 18F-DCFPyL uptake (26/31)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prostate bed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pelvic lymph node</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Nonpelvic lymph node</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bone</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Viscera</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of 18F-DCFPyL PET/CT Findings With Prostate Specific Antigen (PSA) Levels</title>
        <description>Number of participants with PSA 0.2-1.0ng/mL OR PSA &gt;1.0ng/mL with at least 1 site of uptake of 18F-DCFPyL consistent with prostate cancer.</description>
        <time_frame>6 months</time_frame>
        <population>Only 22/31 participants had a PSA of 0.2-1.0ng/mL and 9/31 participants had PSA &gt;1.0ng/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>18F-DCFPyL PET/CT</title>
            <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of 18F-DCFPyL PET/CT Findings With Prostate Specific Antigen (PSA) Levels</title>
          <description>Number of participants with PSA 0.2-1.0ng/mL OR PSA &gt;1.0ng/mL with at least 1 site of uptake of 18F-DCFPyL consistent with prostate cancer.</description>
          <population>Only 22/31 participants had a PSA of 0.2-1.0ng/mL and 9/31 participants had PSA &gt;1.0ng/mL.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA 0.2-1.0 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA &gt;1.0 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Findings on 18FDCFPyL PET/CT With Those Found on Conventional Imaging (Bone Scan and Cross-sectional Imaging)</title>
        <description>Number of sites with uptake on 18F-DCFPyL PET/CT and corresponding lesions identified on conventional imaging.</description>
        <time_frame>6 months</time_frame>
        <population>Data was not collected for this outcome as participants did not have conventional imaging correlates.</population>
        <group_list>
          <group group_id="O1">
            <title>18F-DCFPyL PET/CT</title>
            <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Findings on 18FDCFPyL PET/CT With Those Found on Conventional Imaging (Bone Scan and Cross-sectional Imaging)</title>
          <description>Number of sites with uptake on 18F-DCFPyL PET/CT and corresponding lesions identified on conventional imaging.</description>
          <population>Data was not collected for this outcome as participants did not have conventional imaging correlates.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Findings on 18F-DCFPyL PET/CT With Tissue Histology and PSMA Expression of Biopsied/Resected Pathology Specimens</title>
        <description>Number of sites with 18F-DCFPyL uptake from which biopsy specimens show PSMA expression.</description>
        <time_frame>6 months</time_frame>
        <population>Data was not collected to assess this outcome measure as confirmatory biopsy was not practical to perform and histopathologic confirmation is not available.</population>
        <group_list>
          <group group_id="O1">
            <title>18F-DCFPyL PET/CT</title>
            <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Findings on 18F-DCFPyL PET/CT With Tissue Histology and PSMA Expression of Biopsied/Resected Pathology Specimens</title>
          <description>Number of sites with 18F-DCFPyL uptake from which biopsy specimens show PSMA expression.</description>
          <population>Data was not collected to assess this outcome measure as confirmatory biopsy was not practical to perform and histopathologic confirmation is not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of 18F-DCFPyL PET/CT Findings With Time to Disease Progression</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessment of Treatment Response by 18F-DCFPyL PET/CT</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>18F-DCFPyL PET/CT</title>
          <description>Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
18F-DCFPyL: 18F-DCFPyL PET/CT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Rowe, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4105028052</phone>
      <email>srowe8@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

